Cyclerion Therapeutics, Inc. (CYCN)

NASDAQ: CYCN · IEX Real-Time Price · USD
3.200
+0.030 (0.95%)
At close: Mar 28, 2024, 3:58 PM
3.040
-0.160 (-5.00%)
After-hours: Mar 28, 2024, 7:55 PM EDT
0.95%
Market Cap 8.35M
Revenue (ttm) n/a
Net Income (ttm) -5.26M
Shares Out 2.71M
EPS (ttm) -2.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 18,634
Open 3.200
Previous Close 3.170
Day's Range 3.200 - 3.450
52-Week Range 1.750 - 9.120
Beta 1.77
Analysts n/a
Price Target n/a
Earnings Date May 10, 2024

About CYCN

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is Zagociguat (CY6463), a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Regina Graul Ph.D.
Employees 1
Stock Exchange NASDAQ
Ticker Symbol CYCN
Full Company Profile

Financial Performance

Financial Statements

News

Cyclerion Appoints Regina Graul, Ph.D., as President

– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy –

4 months ago - GlobeNewsWire

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

- Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurologic...

4 months ago - GlobeNewsWire

Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets

– Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment –

8 months ago - GlobeNewsWire

Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement

CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (“Cyclerion” or the “Company”) (Nasdaq: CYCN) today announced that it has received a formal notice from The Nasdaq Stoc...

10 months ago - GlobeNewsWire

Cyclerion Announces Reverse Stock Split

CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (the “Company”, “Cyclerion Therapeutics”, “Cyclerion”) (Nasdaq: CYCN) announced today that it will effect a reverse stoc...

11 months ago - GlobeNewsWire

Cyclerion Announces Definitive Agreement for Zagociguat and CY3018

Certain Cyclerion shareholders and new investors have agreed to invest $81M to launch a new company targeting diseases of mitochondrial dysfunction

11 months ago - GlobeNewsWire

Cyclerion Announces Corporate Updates and Q1 2023 Financial Results

Definitive agreement reached with new company (“NewCo”) established by certain Cyclerion shareholders and new investors

11 months ago - GlobeNewsWire

Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement

CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the Company, acting solely by all of its independent and...

1 year ago - GlobeNewsWire

Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases

CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments for serious diseases, to...

1 year ago - GlobeNewsWire

Cyclerion Reports Corporate Update and Full Year 2022 Financial Results

CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced corporate updates including advances in its zagociguat (formerly CY6463) mitochondrial ...

1 year ago - GlobeNewsWire

Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company

CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the Company acting solely by all of its independent and d...

1 year ago - GlobeNewsWire

Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy

Recent positive MELAS clinical study data drive urgency to deliver potential first-ever therapy for patients with rare, genetic mitochondrial diseases

1 year ago - GlobeNewsWire

Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results

Positive topline results for CY6463 announced in two clinical studies in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive Impairment Associ...

1 year ago - GlobeNewsWire

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)

Study data demonstrate positive effects of CY6463 on cognition and inflammation after two weeks of dosing in patients with stable schizophrenia on standard of care

1 year ago - GlobeNewsWire

Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics' Board of Directors

Renowned neuroscience leader to further long-term clinical research strategy and external collaborations Renowned neuroscience leader to further long-term clinical research strategy and external colla...

1 year ago - GlobeNewsWire

Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Data for CY6463, a first-in-class, CNS-penetrant, sGC stimulator, demonstrate safety and positive effects across biomarkers of disease in MELAS patients

1 year ago - GlobeNewsWire

Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Company to discuss positive topline and additional clinical data for CY6463 in MELAS patients

1 year ago - GlobeNewsWire

Cyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies

Cyclerion Therapeutics Inc's (NASDAQ: CYCN) preclinical studies demonstrated its lead soluble guanylate cyclase (sGC) stimulator, CY6463, improved cellular energetics and reduced inflammation in precl...

1 year ago - Benzinga

Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease

CY6463 alleviated mitochondrial dysfunction and reduced inflammation in preclinical models of mitochondrial complex 1 deficiency

1 year ago - GlobeNewsWire

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium

Data from an eight-patient, open-label study demonstrate improvements across multiple biomarkers of mitochondrial function, inflammation, cerebral blood flow, and functional connectivity

1 year ago - GlobeNewsWire

Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium

Topline results to be shared during the clinical trial update platform session

1 year ago - GlobeNewsWire

Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results

Characterizing the novel neuropharmacology of CY6463's NO-sGC-cGMP signal modulation in an integrated clinical strategy currently involving three ongoing, exploratory, biomarker-rich, signal seeking s...

2 years ago - GlobeNewsWire

Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates

Phase 2a study in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) enrollment closed; topline data expected in Q2 2022

2 years ago - GlobeNewsWire

Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration

Collaboration to identify patient-selection biomarkers for Cyclerion's investigational therapeutics in neurological and neuropsychiatric diseases associated with cognitive impairment Collaboration to ...

2 years ago - GlobeNewsWire

Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer's Disease with Vascular Pathology

Study to evaluate safety, tolerability, pharmacokinetics, and potential to improve cognition Study to evaluate safety, tolerability, pharmacokinetics, and potential to improve cognition

2 years ago - GlobeNewsWire